Cargando…
A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention
BACKGROUND: Patients with coronary artery disease (CAD) combined with diabetes have a higher risk of cardiovascular events, and high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) is a novel inflammatory biomarker. However, whether the CAR can identify high-risk patients with CAD and...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901126/ https://www.ncbi.nlm.nih.gov/pubmed/36747210 http://dx.doi.org/10.1186/s13098-022-00977-9 |
_version_ | 1784882978272313344 |
---|---|
author | Li, Jiawen Zhu, Pei Li, Yulong Yan, Kailun Tang, Xiaofang Xu, Jingjing Yang, Weixian Qiao, Shubin Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Zhao, Xueyan |
author_facet | Li, Jiawen Zhu, Pei Li, Yulong Yan, Kailun Tang, Xiaofang Xu, Jingjing Yang, Weixian Qiao, Shubin Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Zhao, Xueyan |
author_sort | Li, Jiawen |
collection | PubMed |
description | BACKGROUND: Patients with coronary artery disease (CAD) combined with diabetes have a higher risk of cardiovascular events, and high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) is a novel inflammatory biomarker. However, whether the CAR can identify high-risk patients with CAD and type 2 diabetes (T2DM) remains unclear. METHODS: The present study was based on a prospective and observational cohort with 10,724 individuals who undergo percutaneous coronary intervention (PCI) in Fu Wai Hospital throughout the year 2013 consecutively enrolled. The primary endpoint was all-cause mortality. The secondary endpoint was cardiac mortality. CAR was calculated with the formula: hs-CRP (mg/L)/albumin (g/L). According to the optimal cut-off value of CAR for all-cause mortality, patients were divided into higher CAR (CAR-H) and lower CAR (CAR-L) groups. RESULTS: A total of 2755 patients with T2DM who underwent PCI and received dual antiplatelet therapy were finally enrolled. During a follow-up of 5 years (interquartile range: 5.0–5.1 years), 126 (4.6%) all-cause mortalities and 74 (2.7%) cardiac mortalities were recorded. In the multivariable Cox model, CAR-H was associated with a higher risk of all-cause mortality (hazard ratio [HR]: 1.634, 95% confidence interval [CI] 1.121–2.380, p = 0.011) and cardiac mortality (HR: 1.733, 95% CI 1.059–2.835, p = 0.029) compared with CAR-L. When comparing the predictive value, CAR was superior to hs-CRP for all-cause mortality (area under the curve [AUC] 0.588 vs. 0.580, p = 0.002) and cardiac mortality (AUC 0.602 vs. 0.593, p = 0.004). CONCLUSION: In this real-world cohort study, a higher level of CAR was associated with worse 5-year outcomes among diabetic patients with PCI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-022-00977-9. |
format | Online Article Text |
id | pubmed-9901126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-99011262023-02-07 A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention Li, Jiawen Zhu, Pei Li, Yulong Yan, Kailun Tang, Xiaofang Xu, Jingjing Yang, Weixian Qiao, Shubin Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Zhao, Xueyan Diabetol Metab Syndr Research BACKGROUND: Patients with coronary artery disease (CAD) combined with diabetes have a higher risk of cardiovascular events, and high-sensitivity C-reactive protein (hs-CRP)-to-albumin ratio (CAR) is a novel inflammatory biomarker. However, whether the CAR can identify high-risk patients with CAD and type 2 diabetes (T2DM) remains unclear. METHODS: The present study was based on a prospective and observational cohort with 10,724 individuals who undergo percutaneous coronary intervention (PCI) in Fu Wai Hospital throughout the year 2013 consecutively enrolled. The primary endpoint was all-cause mortality. The secondary endpoint was cardiac mortality. CAR was calculated with the formula: hs-CRP (mg/L)/albumin (g/L). According to the optimal cut-off value of CAR for all-cause mortality, patients were divided into higher CAR (CAR-H) and lower CAR (CAR-L) groups. RESULTS: A total of 2755 patients with T2DM who underwent PCI and received dual antiplatelet therapy were finally enrolled. During a follow-up of 5 years (interquartile range: 5.0–5.1 years), 126 (4.6%) all-cause mortalities and 74 (2.7%) cardiac mortalities were recorded. In the multivariable Cox model, CAR-H was associated with a higher risk of all-cause mortality (hazard ratio [HR]: 1.634, 95% confidence interval [CI] 1.121–2.380, p = 0.011) and cardiac mortality (HR: 1.733, 95% CI 1.059–2.835, p = 0.029) compared with CAR-L. When comparing the predictive value, CAR was superior to hs-CRP for all-cause mortality (area under the curve [AUC] 0.588 vs. 0.580, p = 0.002) and cardiac mortality (AUC 0.602 vs. 0.593, p = 0.004). CONCLUSION: In this real-world cohort study, a higher level of CAR was associated with worse 5-year outcomes among diabetic patients with PCI. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-022-00977-9. BioMed Central 2023-02-06 /pmc/articles/PMC9901126/ /pubmed/36747210 http://dx.doi.org/10.1186/s13098-022-00977-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Li, Jiawen Zhu, Pei Li, Yulong Yan, Kailun Tang, Xiaofang Xu, Jingjing Yang, Weixian Qiao, Shubin Yang, Yuejin Gao, Runlin Xu, Bo Yuan, Jinqing Zhao, Xueyan A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
title | A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
title_full | A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
title_fullStr | A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
title_full_unstemmed | A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
title_short | A novel inflammatory biomarker, high-sensitivity C-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
title_sort | novel inflammatory biomarker, high-sensitivity c-reactive protein-to-albumin ratio, is associated with 5-year outcomes in patients with type 2 diabetes who undergo percutaneous coronary intervention |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901126/ https://www.ncbi.nlm.nih.gov/pubmed/36747210 http://dx.doi.org/10.1186/s13098-022-00977-9 |
work_keys_str_mv | AT lijiawen anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT zhupei anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT liyulong anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yankailun anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT tangxiaofang anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT xujingjing anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yangweixian anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT qiaoshubin anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yangyuejin anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT gaorunlin anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT xubo anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yuanjinqing anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT zhaoxueyan anovelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT lijiawen novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT zhupei novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT liyulong novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yankailun novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT tangxiaofang novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT xujingjing novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yangweixian novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT qiaoshubin novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yangyuejin novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT gaorunlin novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT xubo novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT yuanjinqing novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention AT zhaoxueyan novelinflammatorybiomarkerhighsensitivitycreactiveproteintoalbuminratioisassociatedwith5yearoutcomesinpatientswithtype2diabeteswhoundergopercutaneouscoronaryintervention |